nevirapine has been researched along with Acquired Immune Deficiency Syndrome in 151 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 9.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| "To report a case of nevirapine-induced Stevens-Johnson syndrome (SJS) misdiagnosed as viral keratitis." | 7.74 | Nevirapine-induced Stevens-Johnson syndrome in an HIV patient. ( Jain, V; Natarajan, S; Shome, D, 2008) |
| "The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naïve Chinese patients with HIV-1 infection." | 5.13 | Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. ( Dai, Y; Han, Y; Jiang, J; Kuang, J; Li, T; Li, Y; Qiu, Z; Xie, J; Zuo, L, 2008) |
| " The objective of this study was to assess the impact of body weight on the pharmacokinetic disposition of nelfinavir (NFV) in the absence and presence of nevirapine (NVP) and compare the pharmacokinetic profiles of twice-daily (BID) and three-times-daily (TID) NFV regimens." | 5.10 | Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. ( Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A, 2003) |
| "To investigate the incidence of hepatotoxicity in acquired immunodeficiency syndrome (AIDS) patients on combined anti-retroviral therapy (cART) containing nevirapine (NVP) and to assess the risk factors and its impact on cART." | 3.76 | [Nevirapine related hepatotoxicity: the prevalence and risk factors in a cohort of ART naive Han Chinese with AIDS]. ( Deng, LP; Gao, SC; Gui, XE; Liang, K; Rong, YP; Yan, YJ; Yang, RR; Zhang, YX, 2010) |
| "To report a case of nevirapine-induced Stevens-Johnson syndrome (SJS) misdiagnosed as viral keratitis." | 3.74 | Nevirapine-induced Stevens-Johnson syndrome in an HIV patient. ( Jain, V; Natarajan, S; Shome, D, 2008) |
| " As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
| "In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine." | 2.75 | Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. ( Gulick, RM; Kmack, A; Krambrink, A; Kuritzkes, DR; Ribaudo, HJ; Schouten, JT; Shikuma, C; Webb, N, 2010) |
| "Patients with Acquired Immunodeficiency Syndrome (AIDS) were recruited under the Federal Government Highly Active Antiretroviral Therapy (HAART) programme at the University of Ilorin Teaching Hospital." | 2.73 | Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin. ( Iseniyi, JO; Odeigah, L; Olatunji, PO; Olawumi, HO; Salami, AK, 2008) |
| " Our data indicate that NVP prophylaxis for 6 months was safe and well tolerated in infants." | 2.71 | Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. ( Abdool Karim, SS; Bassett, MT; Coovadia, HM; Emel, L; Eshleman, SH; Fleming, T; George, K; Jones, SA; Katzenstein, DA; Maldonado, Y; Maponga, CC; Mirochnick, MM; Mofenson, LM; Mwatha, A; Shetty, AK; Wells, J, 2003) |
| "The complexity of highly active antiretroviral therapy (HAART), with multiple medications, formulations, and dosing intervals, makes adherence challenging." | 2.70 | Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. ( Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A, 2002) |
| "Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy." | 2.70 | Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3 ( Bazin, B; Britto, P; Chaix, ML; Cunningham, CK; Delfraissy, JF; Dorenbaum, A; Gelber, RD; Mofenson, L; Rekacewicz, C; Rouzioux, C; Sullivan, JL, 2002) |
| " The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated." | 2.69 | Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ( D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ, 1999) |
| "The study was conducted among 42 adult AIDS Clinical Trials Group sites and 7 National Hemophilia Foundation centers." | 2.69 | A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T ( Balfour, HH; Erice, A; Fischl, MA; Henry, K; Hirsch, MS; Kahn, JO; Kenton, A; Kmack, A; Liou, SH; Martinez, A; Phair, J; Tierney, C, 1998) |
| "In a multivariate model, risk for disease progression was reduced by 56% (95% CI, 8% to 79% [P = 0." | 2.68 | Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. ( Basgoz, N; Bremer, JW; D'Aquila, RT; Elbeik, T; Erice, A; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Kuritzkes, DR; Scott, WA; Spector, SA, 1997) |
| " Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children." | 2.68 | Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. ( Bryson, Y; Cort, S; Lamson, M; Luzuriaga, K; McSherry, G; Robinson, J; Scott, G; Stechenberg, B; Sullivan, JL, 1996) |
| " There was no statistically significant difference between once daily or twice-daily dosing of NVP, when used in combination with 3TC and d4T (RR = 1." | 2.43 | Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. ( Mahomed, FA; Rutherford, GW; Siegfried, NL; Van Deventer, PJ, 2006) |
| "Thrombocytosis was associated with higher CD4 + cell count, younger age, and use of lamivudine or nevirapine, and did not impact survival." | 1.91 | Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. ( Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham, E; Scheurer, M; Wanless, SR, 2023) |
| "Treatment of HIV has reduced HIV/AIDS-related mortality." | 1.46 | Community Based Antiretroviral Treatment in Rural Zimbabwe. ( Chimukangara, B; Katzenstein, D; Manasa, J; Masimirembwa, C; Mitchell, R; Nyabadza, G, 2017) |
| "A retrospective analysis in HIV/AIDS patients with drug eruption was carried out with demographic data, epidemiological data, clinical characteristics, laboratory data and follow-up data." | 1.43 | Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. ( Bai, JS; Chen, JH; He, LP; Jin, YM; Kuang, YQ; Li, YY; Liu, J; Wen, J; Yu, M, 2016) |
| "To investigate the survival rate of AIDS patients after receiving antiretroviral therapy(ART) in Henan province and to determine factors associated with survival status." | 1.42 | [Survival analysis of AIDS patients of 15 years or above years old after initiation antiretroviral treatment in Henan province during 2005 to 2014]. ( Fan, P; Li, N; Liang, Y; Nie, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| "Data on AIDS patients initially starting antiretroviral therapy during 2008 and 2013 were collected from Chinese HIV/AIDS integrated control system." | 1.42 | [Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013]. ( Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| " Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated." | 1.42 | Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. ( Baum, MM; Beliveau, M; Cortez, JM; Moss, JA; Quintero, R; Smith, TJ, 2015) |
| "The surrogate markers of HIV/AIDS progression include CD4 T cell count and plasma viral load." | 1.40 | MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy. ( Holla, P; Jameel, S; Munshi, SU; Panda, H; Rewari, BB, 2014) |
| "A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions was studied." | 1.39 | AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. ( Borok, MZ; Campbell, TB; Makadzange, AT; Mhlanga, TO; Nelson, BC, 2013) |
| "Nevirapine accumulation was 37% lower in HEK293-ABCC10 cells compared with parental HEK293 cells (P=0." | 1.38 | Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. ( Back, DJ; Brockmeyer, NH; Fätkenheuer, G; Hoffmann, C; Hopper-Borge, E; Khoo, SH; Knechten, H; Liptrott, NJ; Mauss, S; Owen, A; Pirmohamed, M; Pushpakom, S; Siccardi, M; Wyen, C, 2012) |
| " Ten percent (13/123) of the subjects discontinued the treatment due to adverse events." | 1.38 | Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. ( Blanch, J; Cervantes, M; Domingo, P; Ferrer, E; Knobel, H; Llibre, JM; Mallolas, J; Pedrol, E; Vallecillo, G, 2012) |
| "Nevirapine is a poorly water-soluble antiretroviral drug." | 1.37 | In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. ( Jansch, M; Müller, RH; Shegokar, R; Singh, KK, 2011) |
| "Two hundred and thirty-five (235) AIDS patients who received ART were monitored for ADRs over a period of 6 months." | 1.36 | Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study. ( Gupta, U; Kumar, S; Nagpal, M; Tayal, V, 2010) |
| "The treatment of AIDS remains a serious challenge owing to high genetic variation of Human Immunodeficiency Virus type 1 (HIV-1)." | 1.36 | Development of a liposomal nanodelivery system for nevirapine. ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S, 2010) |
| "We describe a 51-year-old female with acquired immunodeficiency syndrome (AIDS) and HIV-associated PAH." | 1.36 | Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. ( Backman, ES; Farber, HW; Hardy, H, 2010) |
| "to give a description of HIV-AIDS and tuberculosis co-infection in Jakarta, viewed from the perspective of virologic and immunologic status and the correct selection of antiretrovirals." | 1.35 | Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital. ( Djoerban, Z; Sumantri, S, 2008) |
| "Transmission prophylaxis in offspring of HIV-positive mothers may give rise to adverse effects." | 1.34 | [Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants]. ( Bauer, K; Dunsch, D; Haberl, A; Linde, R; Reitter, A; Schlösser, R, 2007) |
| "A 31-year-old man with the acquired immunodeficiency syndrome who developed toxic epidermal necrolysis (TEN) was successfully treated with intravenous immunoglobulin." | 1.30 | Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. ( Adelstein, S; Crotty, K; Phan, TG; Wong, RC, 1999) |
| "Nevirapine was rapidly absorbed at all doses from a tablet formulation." | 1.29 | Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. ( Andrews, C; Bova, CA; Cheeseman, SH; Hattox, SE; Keirns, JJ; Koup, RA; McLaughlin, MM; Pav, JW; Roy, T; Sullivan, JL, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (21.19) | 18.2507 |
| 2000's | 85 (56.29) | 29.6817 |
| 2010's | 31 (20.53) | 24.3611 |
| 2020's | 3 (1.99) | 2.80 |
| Authors | Studies |
|---|---|
| Barreca, ML | 1 |
| Rao, A | 1 |
| De Luca, L | 1 |
| Iraci, N | 1 |
| Monforte, AM | 1 |
| Maga, G | 2 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Balzarini, J | 1 |
| Chimirri, A | 1 |
| Yeh, RF | 1 |
| Rezk, NL | 1 |
| Kashuba, AD | 1 |
| Dumond, JB | 1 |
| Tappouni, HL | 1 |
| Tien, HC | 1 |
| Chen, YC | 1 |
| Vourvahis, M | 1 |
| Horton, AL | 1 |
| Fiscus, SA | 1 |
| Patterson, KB | 1 |
| Adedeji, TA | 1 |
| Adedeji, NO | 1 |
| Ajeigbe, AK | 1 |
| Smith, OS | 1 |
| Jeje, OA | 1 |
| Fawale, MB | 1 |
| Ajose, AO | 1 |
| Adebisi, SA | 1 |
| Akande, AA | 1 |
| Okesina, BA | 1 |
| Lubega, J | 1 |
| Kim, TO | 1 |
| Airewele, G | 1 |
| Grimes, A | 1 |
| Bulsara, S | 1 |
| Peckham, E | 1 |
| Wanless, SR | 1 |
| Haq, H | 1 |
| Elyanu, P | 1 |
| Musoke, P | 3 |
| Lumumba, M | 1 |
| Kekitiinwa, A | 1 |
| Matshaba, M | 1 |
| Scheurer, M | 1 |
| Despotovic, J | 1 |
| Wu, X | 1 |
| Wu, G | 1 |
| Ma, P | 1 |
| Wang, R | 1 |
| Li, L | 1 |
| Chen, Y | 1 |
| Xu, J | 1 |
| Li, Y | 2 |
| Li, Q | 1 |
| Yang, Y | 1 |
| Wang, L | 1 |
| Xin, X | 1 |
| Qiao, Y | 1 |
| Fu, G | 1 |
| Huang, X | 1 |
| Su, B | 1 |
| Zhang, T | 2 |
| Wang, H | 1 |
| Zou, H | 1 |
| Mulisa, D | 1 |
| Tesfa, M | 1 |
| Mullu Kassa, G | 1 |
| Tolossa, T | 1 |
| Chimukangara, B | 1 |
| Manasa, J | 1 |
| Mitchell, R | 1 |
| Nyabadza, G | 1 |
| Katzenstein, D | 1 |
| Masimirembwa, C | 1 |
| Nelson, BC | 1 |
| Borok, MZ | 1 |
| Mhlanga, TO | 1 |
| Makadzange, AT | 1 |
| Campbell, TB | 1 |
| Taieb, F | 1 |
| Aghokeng, AF | 1 |
| Eymard-Duvernay, S | 1 |
| Chia, JE | 1 |
| Einterz, E | 1 |
| Mpoudi-Ngole, E | 1 |
| Peeters, M | 1 |
| Molina, JM | 1 |
| Delaporte, E | 1 |
| Munshi, SU | 1 |
| Panda, H | 1 |
| Holla, P | 1 |
| Rewari, BB | 1 |
| Jameel, S | 1 |
| Cortez, JM | 1 |
| Quintero, R | 1 |
| Moss, JA | 1 |
| Beliveau, M | 1 |
| Smith, TJ | 1 |
| Baum, MM | 1 |
| Yang, W | 2 |
| Fan, P | 2 |
| Liang, Y | 2 |
| Li, J | 1 |
| Ma, Y | 1 |
| Li, N | 2 |
| Sun, D | 2 |
| Zhu, Q | 2 |
| Wang, Z | 2 |
| Nsagha, DS | 1 |
| Pokam, BT | 1 |
| Assob, JC | 1 |
| Njunda, AL | 1 |
| Kibu, OD | 1 |
| Tanue, EA | 1 |
| Ayima, CW | 1 |
| Weledji, PE | 1 |
| Nie, Y | 1 |
| Aliyu, MH | 1 |
| Blevins, M | 1 |
| Audet, CM | 1 |
| Kalish, M | 1 |
| Gebi, UI | 1 |
| Onwujekwe, O | 1 |
| Lindegren, ML | 1 |
| Shepherd, BE | 1 |
| Wester, CW | 2 |
| Vermund, SH | 1 |
| Li, YY | 1 |
| Jin, YM | 1 |
| He, LP | 1 |
| Bai, JS | 1 |
| Liu, J | 1 |
| Yu, M | 1 |
| Chen, JH | 1 |
| Wen, J | 1 |
| Kuang, YQ | 1 |
| Onah, HE | 1 |
| Ibeziako, N | 1 |
| Nkwo, PO | 1 |
| Obi, SN | 1 |
| Nwankwo, TO | 1 |
| Sumantri, S | 1 |
| Djoerban, Z | 1 |
| Han, JF | 1 |
| Jiang, Y | 1 |
| Li, T | 1 |
| Dai, Y | 1 |
| Kuang, J | 1 |
| Jiang, J | 1 |
| Han, Y | 3 |
| Qiu, Z | 1 |
| Xie, J | 2 |
| Zuo, L | 1 |
| Podzamczer, D | 2 |
| Olmo, M | 1 |
| Sanz, J | 3 |
| Boix, V | 1 |
| Negredo, E | 1 |
| Knobel, H | 2 |
| Domingo, P | 3 |
| Pineda, JA | 1 |
| Vilades, C | 1 |
| Quero, JH | 1 |
| Force, L | 2 |
| Lahoz, JG | 1 |
| Muñoz, P | 1 |
| Llibre, JM | 2 |
| Mariño, A | 1 |
| Ortega, E | 1 |
| Dalmau, D | 1 |
| Gatell, JM | 3 |
| Antón, E | 1 |
| Sola, J | 1 |
| Galindo, MJ | 1 |
| Pedrol, E | 2 |
| Lima, JT | 1 |
| Flores, J | 1 |
| van de Vijver, DA | 1 |
| Derdelinckx, I | 1 |
| Boucher, CA | 2 |
| Olawumi, HO | 1 |
| Olatunji, PO | 1 |
| Salami, AK | 1 |
| Odeigah, L | 1 |
| Iseniyi, JO | 1 |
| Dahl, V | 1 |
| Palmer, S | 1 |
| Guidozzi, F | 1 |
| Black, V | 1 |
| Coulibaly, SM | 1 |
| Oumar, AA | 1 |
| Ag Aboubacrine, S | 1 |
| Coulibaly, S | 1 |
| Koumare, BY | 1 |
| Mariko, E | 1 |
| Traoré, HA | 1 |
| Harama, M | 1 |
| White, YR | 1 |
| Pierre, RB | 1 |
| Steel-Duncan, J | 1 |
| Palmer, P | 1 |
| Evans-Gilbert, T | 1 |
| Moore, J | 1 |
| Rodriguez, B | 1 |
| Christie, CD | 2 |
| Liu, ZY | 2 |
| Guo, FP | 1 |
| Qiu, ZF | 2 |
| Zuo, LY | 1 |
| Li, YL | 1 |
| Li, TS | 2 |
| Schouten, JT | 1 |
| Krambrink, A | 1 |
| Ribaudo, HJ | 1 |
| Kmack, A | 2 |
| Webb, N | 1 |
| Shikuma, C | 1 |
| Kuritzkes, DR | 5 |
| Gulick, RM | 1 |
| Hardy, H | 1 |
| Backman, ES | 1 |
| Farber, HW | 1 |
| Cramer, YS | 1 |
| Rosenkranz, SL | 1 |
| Hall, SD | 1 |
| Szczech, LA | 1 |
| Amorosa, V | 1 |
| Gupta, SK | 1 |
| Ramana, LN | 1 |
| Sethuraman, S | 1 |
| Ranga, U | 1 |
| Krishnan, UM | 1 |
| Boulware, DR | 1 |
| Gao, SC | 1 |
| Gui, XE | 2 |
| Deng, LP | 1 |
| Zhang, YX | 1 |
| Yan, YJ | 1 |
| Rong, YP | 1 |
| Liang, K | 2 |
| Yang, RR | 1 |
| Shegokar, R | 1 |
| Jansch, M | 1 |
| Singh, KK | 1 |
| Müller, RH | 1 |
| Ukwe, CV | 1 |
| Ekwunife, OI | 1 |
| Udeogaranya, OP | 1 |
| Iwuamadi, UI | 1 |
| Vallecillo, G | 1 |
| Mallolas, J | 2 |
| Blanch, J | 1 |
| Ferrer, E | 1 |
| Cervantes, M | 1 |
| Gao, S | 1 |
| Liu, Z | 1 |
| Hu, J | 1 |
| Dong, B | 1 |
| Liptrott, NJ | 1 |
| Pushpakom, S | 1 |
| Wyen, C | 1 |
| Fätkenheuer, G | 1 |
| Hoffmann, C | 1 |
| Mauss, S | 1 |
| Knechten, H | 1 |
| Brockmeyer, NH | 1 |
| Hopper-Borge, E | 1 |
| Siccardi, M | 1 |
| Back, DJ | 1 |
| Khoo, SH | 1 |
| Pirmohamed, M | 1 |
| Owen, A | 1 |
| Li, ZC | 1 |
| Li, HJ | 1 |
| Dai, LL | 1 |
| Gao, YQ | 1 |
| Cai, WP | 1 |
| Li, HY | 1 |
| Huang, XJ | 1 |
| Wu, H | 1 |
| Stitelman, OM | 1 |
| deGruttola, V | 1 |
| Bussmann, H | 1 |
| Marlink, RG | 1 |
| van der Laan, MJ | 1 |
| Bualert, L | 1 |
| Charungkiattikul, W | 1 |
| Thongsuksai, P | 1 |
| Mungthin, M | 1 |
| Siripattanapipong, S | 1 |
| Khositnithikul, R | 1 |
| Naaglor, T | 1 |
| Ravel, C | 1 |
| El Baidouri, F | 1 |
| Leelayoova, S | 1 |
| Tiraboschi, JM | 1 |
| Curto, J | 1 |
| Cárdenes, MA | 1 |
| Casas, E | 1 |
| Castro, A | 1 |
| Echevarría, S | 1 |
| Leal, M | 1 |
| Lopez Bernaldo de Quirós, JC | 1 |
| Moreno, S | 1 |
| Puig, T | 1 |
| Ribera, E | 1 |
| Villalonga, C | 1 |
| Gómez-Sirvent, JL | 1 |
| García-Henarejos, JA | 1 |
| Lopez-Aldeguer, J | 1 |
| Barrufet, P | 1 |
| Santos, I | 1 |
| Asmuth, DM | 1 |
| Ma, ZM | 1 |
| Mann, S | 1 |
| Knight, TH | 1 |
| Yotter, T | 1 |
| Albanese, A | 1 |
| Melcher, GP | 1 |
| Troia-Cancio, P | 1 |
| Hayes, T | 1 |
| Miller, CJ | 1 |
| Pollard, RB | 1 |
| Feeney, ER | 1 |
| van Vonderen, MG | 1 |
| Wit, F | 1 |
| Danner, SA | 3 |
| van Agtmael, MA | 1 |
| Villarroya, F | 1 |
| Capeau, J | 1 |
| Reiss, P | 3 |
| Mallon, PW | 1 |
| Nagpal, M | 1 |
| Tayal, V | 1 |
| Kumar, S | 1 |
| Gupta, U | 1 |
| Frasco, MA | 1 |
| Mack, WJ | 1 |
| Van Den Berg, D | 1 |
| Aouizerat, BE | 1 |
| Anastos, K | 1 |
| Cohen, M | 1 |
| De Hovitz, J | 1 |
| Golub, ET | 1 |
| Greenblatt, RM | 1 |
| Liu, C | 2 |
| Conti, DV | 1 |
| Pearce, CL | 1 |
| Ciccacci, C | 1 |
| Di Fusco, D | 1 |
| Marazzi, MC | 1 |
| Liotta, G | 1 |
| Palombi, L | 1 |
| Novelli, G | 1 |
| Borgiani, P | 1 |
| Cunningham, CK | 1 |
| Chaix, ML | 1 |
| Rekacewicz, C | 1 |
| Britto, P | 1 |
| Rouzioux, C | 1 |
| Gelber, RD | 1 |
| Dorenbaum, A | 1 |
| Delfraissy, JF | 1 |
| Bazin, B | 1 |
| Mofenson, L | 1 |
| Sullivan, JL | 3 |
| Gandhi, R | 1 |
| Flexner, C | 1 |
| Vidal, C | 1 |
| Arnedo, M | 1 |
| Garcia, F | 1 |
| Mestre, G | 1 |
| Plana, M | 1 |
| Cruceta, A | 1 |
| Capon, A | 1 |
| Gallart, T | 1 |
| Miro, JM | 1 |
| Pumarola, T | 1 |
| Sidley, P | 2 |
| Baleta, A | 1 |
| Floren, LC | 1 |
| Wiznia, A | 2 |
| Hayashi, S | 1 |
| Jayewardene, A | 1 |
| Stanley, K | 2 |
| Johnson, G | 1 |
| Nachman, S | 2 |
| Krogstad, P | 2 |
| Aweeka, FT | 1 |
| Basu, P | 1 |
| Bateman, C | 1 |
| Shetty, AK | 1 |
| Coovadia, HM | 1 |
| Mirochnick, MM | 1 |
| Maldonado, Y | 1 |
| Mofenson, LM | 2 |
| Eshleman, SH | 2 |
| Fleming, T | 1 |
| Emel, L | 1 |
| George, K | 1 |
| Katzenstein, DA | 1 |
| Wells, J | 1 |
| Maponga, CC | 1 |
| Mwatha, A | 2 |
| Jones, SA | 1 |
| Abdool Karim, SS | 1 |
| Bassett, MT | 1 |
| Lambert, JS | 1 |
| Harris, DR | 1 |
| Stiehm, ER | 1 |
| Moye, J | 1 |
| Fowler, MG | 2 |
| Meyer, WA | 1 |
| Bethel, J | 1 |
| Basavapathruni, A | 1 |
| Bailey, CM | 1 |
| Anderson, KS | 1 |
| Guay, LA | 1 |
| Brown, ER | 1 |
| Cunningham, SP | 1 |
| Mmiro, F | 2 |
| Jackson, JB | 2 |
| Fleck, F | 1 |
| LaFraniere, S | 1 |
| Solomon, J | 1 |
| Check, E | 2 |
| Steel-Duncan, JC | 1 |
| Pierre, R | 1 |
| Gabay, L | 1 |
| Cohen, J | 1 |
| Zhou, HY | 2 |
| Zheng, YH | 3 |
| Zhang, CY | 2 |
| Ding, PP | 2 |
| Zou, W | 1 |
| Baker, SG | 1 |
| Fitzmaurice, GM | 1 |
| Freedman, LS | 1 |
| Kramer, BS | 1 |
| Kumarasamy, N | 1 |
| Vallabhaneni, S | 1 |
| Cecelia, AJ | 1 |
| Yepthomi, T | 1 |
| Balakrishnan, P | 1 |
| Saghayam, S | 1 |
| Flanigan, TP | 1 |
| Carpenter, CC | 1 |
| Solomon, S | 1 |
| Mayer, KH | 1 |
| Wang, AX | 1 |
| Cao, YZ | 1 |
| Siegfried, NL | 1 |
| Van Deventer, PJ | 1 |
| Mahomed, FA | 1 |
| Rutherford, GW | 1 |
| Forna, F | 1 |
| Liechty, CA | 1 |
| Solberg, P | 1 |
| Asiimwe, F | 1 |
| Were, W | 2 |
| Mermin, J | 2 |
| Behumbiize, P | 1 |
| Tong, T | 1 |
| Brooks, JT | 2 |
| Weidle, PJ | 2 |
| van Leth, F | 1 |
| Wit, FW | 1 |
| Lange, JM | 4 |
| Chen, J | 2 |
| He, Y | 2 |
| Li, H | 2 |
| De Luca, A | 1 |
| Giambenedetto, SD | 1 |
| Trotta, MP | 1 |
| Colafigli, M | 1 |
| Prosperi, M | 1 |
| Ruiz, L | 1 |
| Baxter, J | 1 |
| Clevenbergh, P | 1 |
| Cauda, R | 1 |
| Perno, CF | 1 |
| Antinori, A | 1 |
| Schlösser, R | 1 |
| Linde, R | 1 |
| Dunsch, D | 1 |
| Reitter, A | 1 |
| Haberl, A | 1 |
| Bauer, K | 1 |
| Shen, Z | 1 |
| Liu, M | 1 |
| Ou, QY | 1 |
| Huang, ZL | 1 |
| Wright, E | 1 |
| Brew, BJ | 1 |
| Lal, L | 1 |
| Ali, ST | 1 |
| Arayawichanont, A | 1 |
| Imran, D | 1 |
| Kamarulzaman, A | 1 |
| Kongsaengdao, S | 1 |
| Kruy, L | 1 |
| Merati, TP | 1 |
| Samintharapanya, K | 1 |
| Sarim, C | 1 |
| Tau, G | 1 |
| Thangsing, C | 1 |
| Vin-Samnang, C | 1 |
| Wesselingh, SL | 1 |
| Eyakuze, C | 1 |
| Jones, DA | 1 |
| Starrs, AM | 1 |
| Sorkin, N | 1 |
| Jain, V | 1 |
| Shome, D | 1 |
| Natarajan, S | 1 |
| Wei, HS | 1 |
| Zhao, HX | 1 |
| Liu, YN | 1 |
| Zhao, Y | 1 |
| Han, N | 1 |
| Cheng, J | 1 |
| Zhang, FJ | 1 |
| Buchacz, K | 1 |
| Moore, D | 1 |
| Downing, R | 1 |
| Kigozi, A | 1 |
| Borkowf, CB | 1 |
| Ndazima, V | 1 |
| Chow, YK | 1 |
| Hirsch, MS | 4 |
| Merrill, DP | 1 |
| Bechtel, LJ | 1 |
| Eron, JJ | 1 |
| Kaplan, JC | 1 |
| D'Aquila, RT | 6 |
| Rennie, J | 1 |
| Jäger, H | 1 |
| Cheeseman, SH | 1 |
| Hattox, SE | 1 |
| McLaughlin, MM | 1 |
| Koup, RA | 1 |
| Andrews, C | 1 |
| Bova, CA | 1 |
| Pav, JW | 1 |
| Roy, T | 1 |
| Keirns, JJ | 1 |
| Nowak, MA | 1 |
| Erlander, SR | 1 |
| Chen, IS | 1 |
| Canon, J | 1 |
| Rey, O | 1 |
| Luzuriaga, K | 1 |
| Bryson, Y | 1 |
| McSherry, G | 1 |
| Robinson, J | 1 |
| Stechenberg, B | 1 |
| Scott, G | 1 |
| Lamson, M | 1 |
| Cort, S | 1 |
| de Jong, MD | 2 |
| Vella, S | 2 |
| Carr, A | 1 |
| Imrie, A | 1 |
| French, M | 1 |
| Hoy, J | 1 |
| Sorice, S | 1 |
| Pauluzzi, S | 1 |
| Chiodo, F | 1 |
| Weverling, GJ | 1 |
| van der Ende, ME | 2 |
| Frissen, PJ | 1 |
| Weigel, HM | 1 |
| Kauffmann, RH | 2 |
| Yoon, R | 1 |
| Moroni, M | 2 |
| Hoenderdos, E | 1 |
| Leitz, G | 1 |
| Cooper, DA | 1 |
| Hall, D | 1 |
| Rutschmann, O | 1 |
| Hirschel, B | 1 |
| Hughes, MD | 2 |
| Johnson, VA | 5 |
| Bremer, JW | 1 |
| Elbeik, T | 1 |
| Erice, A | 2 |
| Scott, WA | 1 |
| Spector, SA | 1 |
| Basgoz, N | 1 |
| Fischl, MA | 3 |
| Collins, DO | 1 |
| Sakamoto, A | 1 |
| Wiese, E | 1 |
| Pakker, NG | 1 |
| Roos, MT | 1 |
| van Leeuwen, R | 1 |
| Koot, M | 1 |
| Miedema, F | 1 |
| Schellekens, PT | 1 |
| Henry, K | 1 |
| Tierney, C | 1 |
| Balfour, HH | 1 |
| Liou, SH | 1 |
| Kenton, A | 1 |
| Phair, J | 1 |
| Martinez, A | 1 |
| Kahn, JO | 1 |
| Zhou, XJ | 1 |
| Sheiner, LB | 1 |
| Myers, M | 1 |
| Sommadossi, JP | 1 |
| Floridia, M | 1 |
| Bucciardini, R | 1 |
| Ricciardulli, D | 1 |
| Fragola, V | 1 |
| Pirillo, MF | 1 |
| Weimer, LE | 1 |
| Tomino, C | 1 |
| Giannini, G | 1 |
| Galluzzo, CM | 1 |
| Andreotti, M | 1 |
| Cargnel, A | 1 |
| Alberici, F | 1 |
| De Rienzo, B | 1 |
| Leoncini, F | 2 |
| Fiaccadori, F | 1 |
| Francisci, D | 1 |
| Grillone, W | 1 |
| Ortona, L | 1 |
| Piazza, M | 1 |
| Scalzini, A | 1 |
| Nigra, E | 1 |
| Tumietto, F | 1 |
| Phan, TG | 1 |
| Wong, RC | 1 |
| Crotty, K | 1 |
| Adelstein, S | 1 |
| Brown, AJ | 2 |
| Günthard, HF | 2 |
| Wong, JK | 2 |
| Richman, DD | 3 |
| Martínez, E | 1 |
| Cherry, M | 4 |
| Precious, HM | 1 |
| Leigh Brown, AJ | 1 |
| Hanna, GJ | 1 |
| Savara, AV | 1 |
| Hazelwood, JD | 1 |
| Howse, J | 1 |
| Masland, T | 1 |
| King, P | 1 |
| Birmingham, K | 1 |
| Hayashi, T | 2 |
| Moyle, G | 1 |
| Baldwin, C | 1 |
| Chen, F | 1 |
| Pau, AK | 1 |
| Piscitelli, SC | 1 |
| Akue, JP | 1 |
| Babaki, P | 1 |
| Barre-Sinoussi, F | 1 |
| Charpak, N | 1 |
| de Thé, G | 1 |
| Rea, MF | 1 |
| Huraux, C | 1 |
| Ndiaye, B | 1 |
| Pratomo, H | 1 |
| Samuel, NM | 1 |
| Wilfert, C | 1 |
| Zetterström, R | 1 |
| Lhotska, L | 1 |
| Armstrong, H | 1 |
| Marseille, E | 1 |
| Kahn, JG | 1 |
| Guay, L | 1 |
| Gottlieb, S | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Deray, G | 1 |
| Weinberg, JM | 1 |
| Lagakos, SW | 1 |
| Link, D | 1 |
| Reiter, GS | 1 |
| Jones, TT | 1 |
| Nieuwkerk, PT | 1 |
| Sprangers, MA | 1 |
| Burger, DM | 1 |
| Hoetelmans, RM | 1 |
| Hugen, PW | 1 |
| Schneider, MM | 1 |
| Schrey, G | 1 |
| Meenhorst, PL | 1 |
| Sprenger, HG | 1 |
| Jambroes, M | 1 |
| Chesney, MA | 1 |
| de Wolf, F | 1 |
| Novak, K | 1 |
| Van Dyke, RB | 1 |
| Lee, S | 1 |
| Johnson, GM | 1 |
| Mohan, K | 1 |
| Morse, EV | 1 |
| Krogstad, PA | 1 |
| Cozzi-Lepri, A | 1 |
| Phillips, AN | 1 |
| d'Arminio Monforte, A | 1 |
| Piersantelli, N | 1 |
| Orani, A | 1 |
| Petrosillo, N | 1 |
| Scerbo, A | 1 |
| Tundo, P | 1 |
| Abrescia, N | 1 |
| Campiani, G | 1 |
| Ramunno, A | 1 |
| Nacci, V | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Morelli, E | 1 |
| Novellino, E | 1 |
| Dodi, F | 1 |
| Alessandrini, A | 1 |
| Camera, M | 1 |
| Gaffuri, L | 1 |
| Morandi, N | 1 |
| Pagano, G | 1 |
| Zuniga, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial[NCT01805752] | 369 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| [NCT00618176] | Phase 4 | 198 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection[NCT00013520] | Phase 3 | 1,125 participants | Interventional | Completed | |||
| A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Raltegravir Therapy[NCT00661960] | 25 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000869] | Phase 3 | 2,009 participants | Interventional | Completed | |||
| Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months[NCT00006279] | Phase 1 | 75 participants | Interventional | Completed | |||
| A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates[NCT00006396] | Phase 3 | 1,500 participants | Interventional | Completed | |||
| Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children[NCT00001111] | 35 participants | Interventional | Completed | ||||
| A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children[NCT00000634] | 6 participants | Interventional | Completed | ||||
| A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine[NCT00000770] | Phase 2 | 400 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Three-Arm Study Comparing Combination to Monthly Alternating Nucleoside Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) With a Prior History of Nucleoside Therapy[NCT00001029] | Phase 2 | 654 participants | Interventional | Completed | |||
| A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)[NCT00000781] | Phase 2 | 1,292 participants | Interventional | Completed | |||
| A Comparative Trial of Protease-Containing and Protease-Sparing HAART Regimens in HIV-Infected Adolescents With an Evaluation of Therapeutic Drug Monitoring[NCT00075907] | Phase 3 | 240 participants | Interventional | 2004-07-31 | Completed | ||
| A Multilevel Gaming Intervention for Persons on PrEP[NCT02611362] | 82 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh[NCT00001091] | Phase 1 | 200 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duodenal tissue immune cell subsets were measured by flow cytometry. (NCT00661960)
Timeframe: nine months
| Intervention | % CD3/CD4 T-cells in GALT tissue (Median) |
|---|---|
| Negative Volunteers | 55.3 |
| HIV-postive Randomized to Raltegravir | 11.7 |
| HIV-postive Randomized to NNRTI | 9.9 |
participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 2 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 5 |
"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 3 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 1 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 1 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 5 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 2 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug*hr/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 99.7 |
| At Day 30 Ppm | NA |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 10.78 |
| At Day 30 Ppm | 12.96 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 11.2 |
| At Day 30 Ppm | NA |
(NCT00109590)
Timeframe: at 24 weeks postpartum
| Intervention | log10 copies/mL (Median) |
|---|---|
| Arm A : LPV/r x 7d | 4.3 |
| Arm B : no LPV/r | 3.9 |
| Arm C: LPV/r x 30d | 4.0 |
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
| Intervention | participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 2 |
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 6.08 |
| At Day 30 Ppm | 9.17 |
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
| Intervention | participants (Number) |
|---|---|
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 0 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 3.6 |
| Arm B : no LPV/r | 7.1 |
| Arm C : LPV/r x 30d | 5.3 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A: LPV/r x 7d | 4.9 |
| Arm B: no LPV/r | 9.5 |
| Arm C : LPV/r x 30d | 7.0 |
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 7.1 |
| Arm B : no LPV/r | 12.5 |
| Arm C: LPV/r x 30d | 5.3 |
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
| Intervention | participants (Number) | |
|---|---|---|
| OLA in plasma samples | OLA in PBMC | |
| Arm A : LPV/r x 7d | 0 | 0 |
| Arm B : no LPV/r | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 1 |
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
| Arm A : LPV/r x 7d | 0 | 0 | 0 |
| Arm B : no LPV/r | 1.78 | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 0 | 0 |
Intracellular TFV-DP will be measured in red blood cells using dried blood spots. TFV-DP levels provide a measure of long-term adherence over the preceding month (like hemoglobin A1C). The level of intracellular TFV-DP can be used to estimate how many doses/week the participant is taking on average (e.g. 7/wk on average, 4-7/wk on average, 2-4/wk on average, <2/wk on average). (NCT02611362)
Timeframe: 24 weeks
| Intervention | fmol/punch (Mean) |
|---|---|
| Intervention | 810.4 |
| Comparison | 574.6 |
"The HIV Knowledge Scale assesses knowledge about issues such as risks for HIV, using 5 items with true, false, or do not know response options. Total scores range from 0 to 5. Higher scores indicate greater knowledge." (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 4.1 |
| Comparison | 4.2 |
Rollnick's Readiness Ruler will be used to assess motivation for adherence to medication and medical visits. Respondents rate how ready they are to take PrEP as prescribed on a scale from 1 (not ready) to 10 (ready to be consistent or already consistent) each month. (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 9.1 |
| Comparison | 9.8 |
This six item measure assesses social support for taking medications, going to medical appointments and other tasks related to adherence using Likert style items with a four point scale. Scores range from 6 to 24 Higher scores indicate greater social support. (NCT02611362)
Timeframe: 24 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Intervention | 21.4 |
| Comparison | 21.2 |
8 reviews available for nevirapine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
[Prevention of mother-to-child transmission with single dose nevirapine and human immunodeficiency virus drug resistance].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Resistance, Viral; Humans; Infectious Dise | 2008 |
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV I | 2006 |
AIDS pathogenesis: from models to viral dynamics in patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection | 1995 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Ther | 1997 |
[New therapy reduces AIDS passed to fetuses and costs less].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Female; Health Care Costs | 2000 |
Update on preventing vertical transmission of HIV type 1.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; | 2000 |
[U.S. warns on some use of anti-AIDS drug].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Humans; | 2001 |
Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzodiazepinones; Benzoxazines; Cyclo | 2002 |
28 trials available for nevirapine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive | 2016 |
Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Asian People; CD4 Lymphocyte | 2008 |
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alanine Transaminase; Anti-HIV Agents; Aspartate Am | 2009 |
Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy | 2008 |
[The clinical and biological tolerance of nevirapine among patients with AIDS under treatment at the Hospital of the Point G].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Human | 2007 |
Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiviral Agents; Benzoxazines; Cyclopropanes; F | 2010 |
Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; | 2012 |
Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocyte | 2012 |
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents | 2012 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therap | 2002 |
Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antiretroviral Therapy, Highly Active; Biological Av | 2003 |
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Epidemiologi | 2003 |
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA, Viral; HIV Infections; HIV-1; Humans; Infa | 2003 |
A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Ly | 2005 |
T-cell response of advanced aids patients after highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2005 |
[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Amylases; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2007 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Antiviral Agents; CD4 Lymphocy | 1996 |
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1997 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study T
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Diseas | 1998 |
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Met | 1999 |
A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double | 1999 |
Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Sequence; Anti-HIV Agents; Didanosine; Drug Therapy, | 1999 |
Multiple sites in HIV-1 reverse transcriptase associated with virological response to combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA Mutational Analysis; Double-Blind Method; D | 2000 |
Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Codon; Didanosine; Double-Blind Method; Drug Resistance; Drug Th | 2000 |
Combination trial with nevirapine underway.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Female; HIV-1; Humans; Male | 1996 |
Nevirapine expanded access program begins.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Female; Humans; Male; Nevir | 1996 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti | 2002 |
115 other studies available for nevirapine and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cell Line; Chemis | 2007 |
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; | 2009 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral T | 2022 |
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infection | 2023 |
Associations of modern initial antiretroviral therapy regimens with all-cause mortality in people living with HIV in resource-limited settings: a retrospective multicenter cohort study in China.
Topics: Acquired Immunodeficiency Syndrome; Benzoxazines; China; Cohort Studies; Humans; Lopinavir; Nevirapi | 2023 |
Determinants of first line antiretroviral therapy treatment failure among adult patients on ART at central Ethiopia: un-matched case control study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Case-Control Studies; CD4 Lymphoc | 2019 |
Community Based Antiretroviral Treatment in Rural Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy | 2017 |
AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; | 2013 |
Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sec | 2014 |
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazi | 2014 |
Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.
Topics: Acquired Immunodeficiency Syndrome; Animals; Breast Feeding; Delayed-Action Preparations; Humans; In | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; H | 2015 |
HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Cameroon; Co | 2015 |
[Survival analysis of AIDS patients of 15 years or above years old after initiation antiretroviral treatment in Henan province during 2005 to 2014].
Topics: Acquired Immunodeficiency Syndrome; Anti-Retroviral Agents; China; Drug Therapy, Combination; Female | 2015 |
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly A | 2016 |
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F | 2008 |
Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV | 2008 |
Circulating HIV type 1 drug resistance will have limited impact on the effectiveness of preexposure prophylaxis among young women in Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocyte | 2009 |
Establishment of drug-resistant HIV-1 in latent reservoirs.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R | 2009 |
The obstetric face and challenge of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf | 2009 |
Adherence to antiretroviral drug therapy in children with HIV/AIDS in Jamaica.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; | 2008 |
Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Blotting, Western; | 2009 |
Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.
Topics: Acquired Immunodeficiency Syndrome; Arteries; Bosentan; Drug Interactions; Female; HIV Infections; H | 2010 |
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; HIV- | 2010 |
Development of a liposomal nanodelivery system for nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Analysis of Variance; Calorimetry, Differential Scanning; Choles | 2010 |
Safety, censoring, and intent-to-treat analysis: dangers to generalizability.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Alanine Transaminase; Anti-HIV Agent | 2010 |
[Nevirapine related hepatotoxicity: the prevalence and risk factors in a cohort of ART naive Han Chinese with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-Retroviral Agents; Asian People; Chemica | 2010 |
In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy.
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Animals; Blood Proteins; Chemistry, Pharmaceutical; | 2011 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov | 2010 |
Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycyti | 2012 |
HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alleles; Anti-HIV Agents; Asian People; CD4 Lymphocyte Co | 2012 |
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Benzylisoquinolines; Biomarkers, | 2012 |
Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiretroviral Therapy, Highly Active; Chemic | 2010 |
Autochthonous disseminated dermal and visceral leishmaniasis in an AIDS patient, southern Thailand, caused by Leishmania siamensis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; F | 2012 |
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studi | 2012 |
Adverse drug reactions to antiretroviral therapy in AIDS patients at a tertiary care hospital in India: A prospective observational study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Central Nervous System Diseases; Drug Th | 2010 |
Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxa | 2012 |
ABCC10 rs2125739 polymorphism and nevirapine-induced hepatotoxicity: lack of association in a population from Mozambique.
Topics: Acquired Immunodeficiency Syndrome; Biomarkers, Pharmacological; Humans; Multidrug Resistance-Associ | 2013 |
When will once (-a day) be enough?
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cy | 2000 |
WHO takes major steps to make HIV treatment accessible.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination | 2002 |
South African government to withdraw antiretrovirals for pregnant mothers.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Approval; Female; Humans; Nevirapine; Preg | 2003 |
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr | 2003 |
South African to distribute AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Utilization; Female; Government Programs; | 2003 |
Aid for AIDS--at last.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Culture; Delivery of Health Care; Humans; Infec | 2003 |
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Adenosine Triphosphate; Allosteric Site; Anti-HIV Agents; Bindin | 2004 |
Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).
Topics: Acquired Immunodeficiency Syndrome; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral | 2004 |
[Nevirapine has gained acceptance. Good antiretroviral effect--favorable lipid profile].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Resp | 2003 |
[CROI highlights of D:A:D Study (Data Collection on Adverse Events of Anti-HIV Drugs Study) and 2NN Study. Stepping into the grease pot].
Topics: Acquired Immunodeficiency Syndrome; Adverse Drug Reaction Reporting Systems; Alkynes; Anti-HIV Agent | 2003 |
WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Anti-HIV Agents; Child; Developing Countries; Dis | 2004 |
South Africa rejects use of AIDS drug for women.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas | 2004 |
Research flawed on key AIDS medicine: Bush had planned its use in Africa.
Topics: Acquired Immunodeficiency Syndrome; Africa; Clinical Trials as Topic; Humans; Infant, Newborn; Infec | 2004 |
Activists and researchers rally behind AIDS drug for mothers.
Topics: Acquired Immunodeficiency Syndrome; Africa; Clinical Trials as Topic; Female; Humans; Infant, Newbor | 2004 |
Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Exanthema; HIV Infections; Humans; Infant; Jama | 2004 |
AIDS treatment. A step toward cheaper anti-HIV therapy.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Drug Approval; Drug Combi | 2005 |
Activists angry at fallout from AIDS drug trial allegations.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Female; Humans; Infan | 2005 |
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Humans; Likel | 2006 |
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2006 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, H | 2007 |
Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic | 2007 |
Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiretroviral Therapy, Highly Active; CD4 Ly | 2007 |
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Di | 2007 |
[Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cesarean Section; Female; Gestational Age; HIV | 2007 |
Response to Birbeck et al.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-Retroviral Agents; Anticonvulsa | 2008 |
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries; | 2008 |
Nevirapine-induced Stevens-Johnson syndrome in an HIV patient.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Conjunctival Diseases; Dry Eye Syndromes | 2008 |
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2007 |
Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2008 |
Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Topics: Acquired Immunodeficiency Syndrome; Biological Evolution; Didanosine; DNA, Viral; Drug Resistance, M | 1993 |
Triple whammy. Will an AIDS therapy live up to its advance billing?
Topics: Acquired Immunodeficiency Syndrome; Cells, Cultured; Didanosine; Drug Therapy, Combination; HIV; Hum | 1993 |
Resisting the temptation.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Com | 1993 |
[AIDS: therapeutic changes in the second decade. Triple combination--HIV vaccination].
Topics: Acquired Immunodeficiency Syndrome; AIDS Vaccines; Antiviral Agents; Cross-Sectional Studies; Didano | 1993 |
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Female; Half-Life; HIV Infections; HIV- | 1993 |
The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism.
Topics: Acquired Immunodeficiency Syndrome; Apoptosis; CD4-Positive T-Lymphocytes; Endopeptidases; Eosinophi | 1996 |
Quantitative analysis of the endogenous reverse transcriptase reactions of HIV type 1 variants with decreased susceptibility to azidothymidine and nevirapine.
Topics: Acquired Immunodeficiency Syndrome; Animals; COS Cells; DNA, Viral; Drug Resistance, Microbial; HIV- | 1996 |
Nonnucleoside reverse transcriptase inhibitor marketed for AIDS therapy.
Topics: Acquired Immunodeficiency Syndrome; Drug Approval; HIV Reverse Transcriptase; Humans; Nevirapine; Py | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do | 1996 |
High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; HIV Core Protein p24; HIV-1; Humans; Mid | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th | 1997 |
[Nevirapine--the first non-nucleoside inhibitor of reverse transcriptase in the battle against AIDS].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Humans; Nevirapine; Pyridines; Reverse Transcri | 1997 |
Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; HIV-1; Humans; Nevirapine; Ritonavir; RNA, Vira | 1997 |
Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Humans; Immunoglobulins, Intravenous; Ma | 1999 |
Uganda gives lessons in stemming the AIDS epidemic.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Disease Outbreaks; Female; Government; Health P | 1999 |
[Lipodystrophy and antiretroviral agents].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Prote | 1999 |
Concern at cheap AIDS drug fears.
Topics: Acquired Immunodeficiency Syndrome; Africa, Southern; Anti-HIV Agents; Costs and Cost Analysis; Fema | 1999 |
Focus on AIDS.
Topics: Acquired Immunodeficiency Syndrome; Awareness; Commerce; Humans; Internet; Nevirapine; Politics; Pre | 2000 |
Deaths bring South African HIV drug trials to a premature halt.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug T | 2000 |
Flirting with strange ideas. Mbeki reaches out to a controversial AIDS researcher.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Biochemistry; Clinical Trials as Topic; | 2000 |
[Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Drug Ad | 2000 |
Beanie Baby profits support AIDS foundation.
Topics: Acquired Immunodeficiency Syndrome; Female; Foundations; Humans; Infectious Disease Transmission, Ve | 2000 |
Mbeki gives AIDS scientists the cold shoulder.
Topics: Acquired Immunodeficiency Syndrome; Adult; Breast Feeding; Enzyme-Linked Immunosorbent Assay; Female | 2000 |
Diplomatic Mandela calls for action on HIV...as South Africa considers its options after free drugs offer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Drug Costs; Drug Industry; Female | 2000 |
South African government continues policy of inactivity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal | 2000 |
Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution.
Topics: Acquired Immunodeficiency Syndrome; Adipose Tissue; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynuc | 2000 |
Inexpensive AIDS drug still reduces HIV transmission from mother to child after 1 year.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies | 2000 |
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast | 2000 |
Future directions.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem | 2000 |
The cost effectiveness of a single-dose nevirapine regimen to mother and infant to reduce vertical HIV-1 transmission in sub-Saharan Africa.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-HIV Agents; Computer Simulation | 2000 |
Nevirapine should not be prescribed for needlestick injuries.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Anti-HIV Agents; Chemical and Drug Induced Liver | 2001 |
Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; HIV Protease Inhibitors; HIV-1; Humans; | 2001 |
Efficiency comparisons of rank and permutation tests based on summary statistics computed from repeated measures data.
Topics: Acquired Immunodeficiency Syndrome; Adenine; HIV-1; Humans; Nevirapine; Organophosphonates; Protease | 2001 |
South Africa cuts agreement for one AIDS drug but ignores another.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cost Savings; Drug Indust | 2001 |
Viramune Expanded Access Program begins.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drugs, Investigational; Female; HIV Infections; | 1996 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
Nevirapine-plus-protease studies under way.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Protease Inhibit | 1996 |
Hepatitis in an HIV-infected man.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alcohol Drinking; Anti-HIV Agents; Drug Therapy, Combinat | 1997 |
South Africa in crisis on HIV/AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Industry; Female; Health Policy; Health Se | 2001 |
AIDS campaigners to take South Africa's health ministry to court.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Condoms; Delivery of Health Care; Drug Costs; H | 2001 |
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Sche | 2001 |
Faculty demands AIDS drugs for all.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Industry; Faculty, Medical; Health Policy; | 2002 |
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly | 2002 |
Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Hepatitis C, Chronic; HIV Infections; Hu | 2002 |
[Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical | 2002 |
[Delayed virus suppression has its price. Heart and liver are no longer secondary theaters].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical | 2002 |
No acceptable excuse for inaction.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Priorities; Health Services Accessibility; Humans | 2002 |
New AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Anthracenes; Antiviral Agents; Azepines; Humans; Nevirapine; Per | 1991 |